An early trial is under way to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT-413 in patients with MYD88 mutant and MYD88 wild-type relapsed or refractory DLBCL when administered intravenously (NCT05233033). Here, MYD88 is linked to diffuse large B-cell lymphoma.